Spondyloarthritides (SpAs) are a group of common rheumatic diseases that often cause limited mobility and lower back pain. Physiotherapy is an integral part of treatment, but access to physiotherapy limits treatment success. Digital health applications (DHAs) enable home-based physiotherapy and could significantly improve access for SpAs patients. The aim is to investigate the clinical effects of the DHA ViViRA compared with those of standard physiotherapy. SpAs patients with chronic back pain were enrolled in a randomized controlled trial. The intervention group received ViViRA DHA, whereas the control group received standard physiotherapy. Pain (verbal rating scale, PAIN-Detect), quality of life (SF-36) and mobility (BASMI) were assessed at baseline and after 12 weeks as the primary outcomes. Data from 59 participants (71.2% female, mean age 45.2 years) were analyzed. The intervention group showed a significant improvement in mobility (average BASMI score: baseline: 1.1 [range 0.7–1.5]; follow-up: 1.0 [range 0.5–1.4]; p = 0.05), whereas the control group showed a significant decrease in mobility (baseline: 1.5 [range 1.1–1.9]; follow-up: 1.8 [range 1.4–2.2]; p = 0.00). The intervention group demonstrated lower pain intensity (VRS pain level at week 3.5 ± 2.8) than did the control group (VRS pain level at week 4.5 ± 2) after 12 weeks. Our results highlight the efficacy of DHAs such as ViViRA in the treatment of lower back pain in SpAs patients. Compared with the current gold standard, physiotherapy, DHA use results in superior outcomes. However, further larger studies are needed to confirm these promising results. The study is registered in the German clinical trial registry (DRKS) under the following ID: DRKS00031254.

中文翻译：

---

数字健康应用程序 ViViRA 对脊柱关节炎患者脊柱活动度、身体功能、生活质量和疼痛感知的影响：一项随机对照试验


脊椎关节炎 （SpAs） 是一组常见的风湿病，通常会导致活动受限和腰痛。物理治疗是治疗不可或缺的一部分，但获得物理治疗会限制治疗的成功率。数字健康应用程序 （DHA） 支持基于家庭的物理治疗，并可以显着改善 SpAs 患者的使用。目的是研究 DHA ViViRA 与标准物理治疗相比的临床效果。患有慢性背痛的 SpAs 患者被纳入一项随机对照试验。干预组接受 ViViRA DHA，而对照组接受标准物理治疗。在基线和 12 周后评估疼痛 （口头评定量表，PAIN-Detect） 、生活质量 （SF-36） 和活动能力 （BASMI） 作为主要结局。分析了来自 59 名参与者 （71.2% 为女性，平均年龄 45.2 岁） 的数据。干预组显示活动能力显着改善（平均 BASMI 评分：基线：1.1 [范围 0.7-1.5];随访：1.0 [范围 0.5-1.4];p = 0.05），而对照组显示活动能力显着下降（基线：1.5 [范围 1.1-1.9];随访：1.8 [范围 1.4-2.2];p = 0.00）。干预组在 12 周后表现出比对照组 （第 4.5 ± 2.8 周的 VRS 疼痛水平） 更低的疼痛强度 （第 3.5 ± 2.8 周的 VRS 疼痛水平）。我们的结果强调了 ViViRA 等 DHA 治疗 SpAs 患者腰痛的疗效。与目前的黄金标准相比，物理治疗，DHA 的使用效果更好。然而，需要进一步更大规模的研究来证实这些有希望的结果。该研究在德国临床试验注册处 （DRKS） 注册，注册号为：DRKS00031254。